Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Language
Publication year range
1.
Arq Bras Oftalmol ; 79(2): 119-20, 2016 Apr.
Article in English | MEDLINE | ID: mdl-27224078

ABSTRACT

Bilateral acute depigmentation of the iris (BADI) is a new clinical entity of unknown etiology and is characterized by bilateral, symmetrical, and simultaneous depigmentation of the iris with focal or diffuse stromal atrophy; this condition generally has a good prognosis. We present a case of a 26-year-old woman who noted a spontaneous change in the iris color in both eyes in the last 2 months. The ophthalmological findings were atrophy of the iris stroma and pigmentation of the trabecular meshwork, without affecting the pigmented epithelium of the iris. Her intraocular pressure was normal and the visual acuity was 20/20 in both eyes.


Subject(s)
Iris/pathology , Pigment Epithelium of Eye/pathology , Pigmentation Disorders/diagnosis , Acute Disease , Adult , Atrophy/diagnosis , Diagnosis, Differential , Female , Humans , Trabecular Meshwork/pathology
2.
Arq. bras. oftalmol ; 79(2): 119-120, Mar.-Apr. 2016. graf
Article in English | LILACS | ID: lil-782796

ABSTRACT

ABSTRACT Bilateral acute depigmentation of the iris (BADI) is a new clinical entity of unknown etiology and is characterized by bilateral, symmetrical, and simultaneous depigmentation of the iris with focal or diffuse stromal atrophy; this condition generally has a good prognosis. We present a case of a 26-year-old woman who noted a spontaneous change in the iris color in both eyes in the last 2 months. The ophthalmological findings were atrophy of the iris stroma and pigmentation of the trabecular meshwork, without affecting the pigmented epithelium of the iris. Her intraocular pressure was normal and the visual acuity was 20/20 in both eyes.


RESUMO A despigmentação aguda bilateral da íris (DABI) é uma nova entidade clínica caracterizada pela despigmentação bilateral, simétrica e simultânea da íris, com atrofia focal ou difusa do seu estroma, geralmente com bom prognóstico. Apresentamos o caso de uma mulher de 26 anos de idade que procurou atendimento médico em nosso serviço com queixa de mudança espontânea na cor da íris de ambos os olhos nos últimos dois meses. Os achados oftalmológicos observados durante o exame clínico foram atrofia do estroma da íris e pigmentação da malha trabecular, sem afetar o epitélio pigmentado da íris. A pressão intraocular era normal e acuidade visual de 20/20 em ambos os olhos.


Subject(s)
Humans , Female , Adult , Pigment Epithelium of Eye/pathology , Pigmentation Disorders/diagnosis , Iris/pathology , Atrophy/diagnosis , Trabecular Meshwork/pathology , Acute Disease , Diagnosis, Differential
3.
J Perinat Med ; 40(3): 225-8, 2012 Jan 10.
Article in English | MEDLINE | ID: mdl-22505499

ABSTRACT

OBJECTIVE: To evaluate the perinatal impact of metformin and glyburide in the treatment of gestational diabetes mellitus (GDM). METHODS: A randomized clinical trial conducted from July 2008 until September 2010 studied 200 pregnant women with GDM who required adjunctive therapy to diet and physical activity. Patients were randomized to use metformin (n=104) or glyburide (n=96). The drugs were replaced by insulin when they reached the maximum dose without glycemic control. Assessed outcomes: weight and neonatal blood glucose. RESULTS: No difference was found (P>0.05) between the groups regarding maternal age, gestational age at inclusion, body mass index, glucose levels in oral glucose tolerance test (OGTT) 75 g and glycemic control. Difference was found in the number of previous pregnancies (2.84 vs. 2.47, P=0.04) and weight gain during pregnancy (7.78 vs. 9.84, P=0.04) in the metformin group and glyburide respectively. The perinatal results showed no difference (P>0.05) in the percentage of cesarean deliveries, gestational age at delivery, number of newborns large for gestational age (LGA), neonatal hypoglycemia, admission to intensive care unit and perinatal death. We found differences in weight (3193 g vs. 3387 g, P=0.01) and ponderal index (2.87 vs. 2.96, P=0.05) of newborns, and in neonatal blood glucose levels at the 1st (59.78 vs. 54.08, P=0.01) and 3rd h (61.53 vs. 55.89, P=0.01) after birth between the metformin and glyburide groups respectively. CONCLUSIONS: Weight and ponderal index were lower in the newborns of the metformin group; glucose levels (1st and 3rd h after birth) were lower in the glyburide group.


Subject(s)
Diabetes, Gestational/drug therapy , Glyburide/therapeutic use , Hypoglycemic Agents/therapeutic use , Metformin/therapeutic use , Adult , Birth Weight/drug effects , Blood Glucose/metabolism , Diabetes, Gestational/pathology , Female , Glucose Tolerance Test , Glyburide/adverse effects , Humans , Hypoglycemic Agents/administration & dosage , Hypoglycemic Agents/adverse effects , Infant, Newborn , Male , Metformin/adverse effects , Pregnancy , Pregnancy Outcome , Weight Gain/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...